Home › Type 1 Diabetes › NCT07676565

Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adults ≥18 years of age
* Clinical diagnosis of T1D
* GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
* Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
* Willing and able to provide informed consent

Exclusion Criteria:

* No exclusion criteria other than those not meeting inclusion criteria above

About the study

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

Sponsor: Indiana University · Participants: 300 · Started: Mar 24, 2026

Contact the study team

• Kanchan Bhasin, MBBS · Phone: (317)-278-2752

Official record on ClinicalTrials.gov — NCT07676565

Locations in the U.S.

Conditions

• Type 1 Diabetes

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.